




























semaine	 post-natale,	 de	 l’hypotonie,	 de	 la	 léthargie,	 et	 survivent	 avec	 un	 retard	
développemental	 et	 des	 convulsions	 intraitables.	 Les	 traitements	 disponibles	 sont	 souvent	









des	 mutants	 présente	 aussi	 un	 déséquilibre	 transitoire	 de	 prolifération	 cellulaire,	 sans	
conséquence	 sur	 les	principaux	 réseaux	nerveux.	Enfin,	nous	 confirmons	que	 le	phénotype	
d’hypotonie	des	mutants	est	dû	à	la	sur-activation	des	récepteurs	NMDA	et	glycinergiques,	et	





























patients	have	a	high	 lethality	 in	the	first	week	of	 life,	hypotonia,	 lethargy,	and	survive	with	
variable	 developmental	 delay	 and	 intractable	 seizures.	 The	 treatments	 available	 are	 often	
inefficient	on	the	severe	form	of	the	disease	and	little	translational	research	has	focused	on	
the	pathogenic	mechanisms	involved	in	GE.	Here,	we	generated	a	zebrafish	model	of	severe	
GE	 by	 knocking	 out	 the	 ortholog	 of	 the	 ‘GLycine	 DeCarboxylase’	 gene	 GLDC,	 commonly	
mutated	 in	 the	 disease.	 We	 show	 that	 the	 gldc	 -/-	 zebrafish	 larvae	 recapitulate	 GE	 on	 a	
molecular	level,	with	reduced	gldc	expression	and	increased	glycine	levels	in	the	body.	Gldc	-





brain	networks.	 Importantly,	we	confirmed	that	the	gldc	 -/-	hypotonic	phenotype	 is	due	to	
NMDA	and	glycine	 receptor	overactivation	and	demonstrated	 that	 there	 is	 an	exacerbated	
hyperglycinemia	 at	 these	 synapses,	 which	 can	 be	 rescued	 pharmacologically	 using	 NMDA	
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Glycine	 encephalopathy	 (GE),	 also	 known	 as	 nonketotic	 hyperglycinemia	 (MIM	





(GLDC),	 an	 aminomethyltransferase	 (AMT),	 a	 hydrogen	 carrier	 protein	 (GCSH),	 and	 a	
dihydrolipoamide	dehydrogenase	 (DLD)	 (figure	 I.1.1)	 [4,	5].	The	glycine	decarboxylase	gene	




Figure	 I.1.1:	 The	 glycine	 cleavage	 system	 (GCS)	 reaction	 yields	 ammonia,	 CO2,	 and	 N	5-N	10-methylene	
tetrahydrofolate.	 The	 GCS	 is	 composed	 of	 4	 proteins:	 glycine	 decarboxylase	 (GLDC),	 tetrahydrofolate	





the	GCS	genes,	which	determine	whether	 there	 is	 residual	GCS	enzymatic	activity.	Patients	
with	residual	GCS	activity	develop	a	more	attenuated	form	of	the	disease	[4].	Individuals	with	
attenuated	 GE	 often	 survive	 the	 neonatal	 period	 but	 show	 treatable	 epilepsy,	 spasticity,	
chorea,	 and	 variable	 developmental	 delay	 that	 can	 lead	 to	 intellectual	 disability	 [4,	 6].		
However,	in	severe	GE	the	neonates	present	severe	hypotonia,	myoclonic	jerks,	lethargy	and	
apnea	due	to	respiratory	depression,	which	often	causes	death	within	the	first	week	of	life.	
The	 neonates	 are	 sometimes	 born	 with	 brain	 malformations,	 such	 as	 hydrocephalus	 and	
 3 
absence	of	 corpus	 callosum	 [2].	 The	patients	with	 severe	GE	 surviving	 the	neonatal	period	
make	no	developmental	progress	and	show	spasticity,	intractable	seizures	and	hypotonia.		
	
The	 treatments	 available	 for	 GE	 patients	 alleviate	 the	 symptoms	 caused	 by	 the	
increased	 glycine	 levels	 but	 do	 not	 resolve	 the	 underlying	 metabolic	 defects.	 Indeed,	
dextromethorphan,	 an	 NMDA	 receptor	 antagonist,	 is	 used	 to	 diminish	 the	 seizures	 in	 GE	
because	 it	 counteracts	 the	 effect	 of	 glycine	 as	 a	 co-agonist	 of	 the	 NMDA	 receptors,	 and	
sodium	 benzoate	 helps	 reduce	 glycine	 levels	 by	 elimination	 through	 the	 urine	 [6].	
Unfortunately,	even	when	combined,	these	treatments	fail	to	improve	the	outcome	of	many	
GE	patients	and	in	the	most	severe	form	starting	the	treatment	early	in	the	neonatal	period	





cause	 of	 the	 disease	 and	 characterize	 the	 spectrum	 of	 symptoms,	 it	 has	 not	 been	 very	
successful	 in	 understanding	 the	 molecular	 basis	 of	 GE.	 Some	 research	 efforts	 have	 been	
made	to	model	the	disease	in	mice	and	zebrafish.	Mouse	knock-outs	of	the	AMT	and	GLDC	
genes	have	been	generated	in	Nicholas	Greene’s	laboratory	[7,	8].	The	GLDC	knock-out	mice	
show	 features	 of	 glycine	 encephalopathy,	 such	 as	 hyperglycinemia,	 early	 lethality,	 and	







newborns.	 Moreover,	 this	 research	 group	 showed	 that	 GLDC	 mutations	 in	 humans	
predispose	 to	 NTDs	 [7].	 In	 their	 work,	 the	 authors	 demonstrate	 that	 there	 was	 partially	
penetrant	NTD	 in	 the	 homozygous	GLDC	mutant	mouse	 embryos,	 decreased	 proliferation,	
and	an	imbalance	in	the	folate	compounds.	They	argue	that	the	higher	NTD	prevalence	is	due	




In	 zebrafish,	 the	shocked	mutant,	 in	which	 the	glycine	 transporter	1	 (GlyT1)	gene	 is	
knocked	 out	 has	 high	 extracellular	 glycine	 in	 the	 brain,	 and	 broad	motor	 defects	 affecting	
spontaneous	coiling	(earliest	motor	output),	the	escape	response,	and	swimming	[10].	GlyT1	
is	 a	 glycine	 transporter	 located	 at	 NMDA-glutamatergic	 synapses,	 on	 glial,	 pre-,	 and	 post-
synaptic	cells,	and	at	glycinergic	synapses	on	glial	cells	solely.	At	glycinergic	synapses,	GlyT1	
acts	 to	 control	 the	 levels	 of	 glycine	 in	 the	 synaptic	 cleft,	 and	 at	 NMDA-glutamatergic	
synapses,	GlyT1	keeps	the	extracellular	concentrations	of	glycine	below	the	saturating	levels	
of	 the	 co-agonistic	 site	 of	NDMA	 receptors	 (figure	 I.1.2)	 [11].	 The	GlyT1	was	 shown	 to	 be	
involved	in	a	subtype	of	GE,	in	which	the	patients	have	a	mild	hyperglycinemia	in	the	central	




The	 lack	 of	 translational	 research	 on	 a	 model	 of	 GE	 and	 the	 need	 of	 finding	 an	

















Glycine	 receptors	 are	 composed	 of	 5	 subunits:	 the	 alpha	 subunits,	 of	 which	 4	 types	 exist	
(GLRA1,	 GLRA2,	 GLRA3,	 GLRA4),	 bind	 glycine	 and	 contain	 the	 pore,	 and	 the	 beta	 subunit	
(GLRB)	anchors	the	receptor	to	the	membrane	through	its	interaction	with	gephyrin	[15].	In	
embryonic	 neurons,	 however,	 glycine	 receptors	 are	 excitatory	 when	 activated,	 due	 to	
increased	 intracellular	 chloride	 concentrations	 in	 immature	 neurons.	 In	 these	 conditions,	
when	 glycine	 binds,	 there	 is	 a	 depolarization	 of	 the	 cell,	 which	 leads	 to	 a	 calcium	 influx	
important	for	development	of	the	neuron,	particularly	for	the	glycinergic	synapse.	When	the	
neuron	matures,	there	is	expression	of	the	extrusive	K+-Cl-	cotransporter	KCC2,	which	lowers	
the	 intracellular	 concentration	of	 chloride.	This	 thereby	 reverses	 the	 flow	of	 this	 ion	when	
the	 glycine	 receptor	 is	 activated,	 leading	 to	 hyperpolarization	 and	 inhibition	 of	 the	 post-
synaptic	cell	[14].	In	the	case	of	GE,	inhibitory	action	of	glycine	on	glycine	receptors	has	been	
associated	with	respiratory	depression	and	hypotonia	[5].	
Glycine	 is	 also	 excitatory	when	 binding	 the	 co-agonist	 site	 on	NDMA-glutamatergic	
receptors	(figure	I.2.1).	NMDA	receptors	are	glutamate-gated	cation	channels	that	have	the	
particularity	 of	 a	 high	 calcium	 permeability	 [16].	 NMDA	 receptors	 are	 tetrameric	 channels	
composed	 of	 a	 combination	 of	 GluN1,	 GluN2,	 and	 GluN3	 heterodimers.	 The	 GluN1	 and	 3	
subunits	 bind	 glycine,	 whereas	 the	 GluN2	 subunit	 binds	 glutamate.	 Each	 subunit	 exists	 in	
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many	variants,	and	the	variety	of	 functions	of	 the	NMDA	receptors	 is	due	to	the	variety	of	
combinations	of	these	subunits	[17].	Activation	of	NMDA	receptors	requires	the	binding	of	L-
glutamate	to	the	GluN2	subunit	and	of	glycine	(or	serine)	to	the	GluN1	subunit,	along	with	a	
simultaneous	 depolarization	 of	 the	 cell	 to	 remove	 the	 magnesium	 ion	 blocking	 the	 pore	
(figure	 I.2.1)	 [18].	NMDA	receptors	are	known	to	be	 important	for	synaptic	plasticity,	more	
particularly	through	long-term	potentiation	and	depression	at	synapses,	processes	crucial	for	
learning	 and	memory	 [19].	 Interestingly,	 NMDA	 receptors	 are	 thought	 to	 be	 implicated	 in	
brain	 development,	 through	 experience	 dependent	 synaptic-plasticity	 [20].	 Moreover,	




chloride	 to	 flow	 in	 the	cell	when	glycine	binds.	Chloride	 flows	 inside	 the	cell,	which	causes	hyperpolarization	
and	inhibition	of	neurotransmission.	Glutamate	binds	to	the	GluN2	subunit	of	the	NMDA	receptor,	while	glycine	
binds	to	the	GluN1	subunit.	At	the	same	time,	a	depolarization	of	the	post-synaptic	cell	 is	required	to	remove	




	 Glycine	 is	 the	 simplest	 amino	acid	and	 in	mammals,	 it	 is	 a	nutritional	non-essential	
amino	acid,	since	it	can	be	also	synthesized	in	the	body.	Although	deficiencies	in	glycine	are	
not	 life	 threatening,	 chronic	 deficiencies	might	 lead	 to	 suboptimal	 growth,	making	 glycine	
essential	for	the	support	of	maximum	growth	[21].	Indeed,	glycine	can	be	synthesized	from	
threonine,	 choline,	 glyoxylate,	 and	 serine.	 All	 these	 reactions	 occur	 at	 various	 rates	
depending	 on	 the	 availability	 of	 glycine	 and	 substrates	 in	 the	 body.	 Threonine	
dehydrogenase	 catalyzes	 threonine	 conversion	 to	 glycine.	 Choline	dehydrogenase	 converts	
choline	 to	 betaine,	 which	 is	 then	 used	 to	 produce	 methionine	 and	 sarcosine;	 sarcosine	
dehydrogenase	 then	catalyzes	 the	production	of	glycine	 from	sarcosine.	Alanine:glyoxylate	
aminotransferase	uses	 the	 amino	 group	 of	 alanine	 and	 glyoxylate	 to	 yield	 glycine.	 The	
serine	 hydroxymethyltransferase	 (SHMT)	 synthesizes	 glycine	 from	 serine,	 and	 converts	
tetrahydrofolate	 to	 its	 activated	 form,	 N	5-N	10-methylene	 tetrahydrofolate,	 that	 is	 then	
incorporated	to	the	folate	one	carbon	metabolism	(FOCM)	(figure	I.2.2)	[21,	22].		
	
The	 major	 pathway	 of	 glycine	 catabolism	 occurs	 through	 the	 GCS,	 which	 yields	
ammonia	 and	 carbon	 dioxide,	 and	 also	 converts	 tetrahydrofolate	 to	 N	5-N	10-methylene	
tetrahydrofolate	 [1].	Glycine	 is	 thus	 an	 important	 carbon	donor	 to	 the	 FOCM,	 crucial	 for	
many	 aspects	 of	 cellular	 functions,	 such	 as	 methylation	 reactions,	 synthesis	 of	 nucleic	
acids,	 proteins,	 lipids,	 proliferation,	 and	 redox	 balance.	 The	 FOCM	 is	 an	 integrator	 of	




to	 produce	 glutathione,	 heme,	 creatine,	 purines,	 and	 serine.	Glutathione	 is	 an	 important	
antioxidant	and	hemes	are	used	for	oxygen	and	mitochondrial	energy	transport.	Creatine	is	
crucial	 to	muscle	 and	 nerve	 energy	metabolism,	 and	 purines	 are	 necessary	 for	 DNA	 and	
protein	 synthesis,	 and	 thus	 cellular	 proliferation	 [21].	 Glycine	 is	 therefore	 involved	 in	 a	














offers	a	lot	of	advantages.	First	of	all,	 it	 is	a	cheap	and	fast	model,	that	 is	very	favorable	to	
the	 study	 of	 development.	 Indeed,	 the	 ex	 vivo	 fertilization	 of	 the	 embryos	 and	 its	
transparency	allow	 to	 follow	 the	development	 from	the	 first	 cell	 to	 the	 larval	 stage.	These	
features	of	the	zebrafish	embryo	also	permit	access	to	the	first	cell	for	injections,	making	it	a	




Secondly,	 as	 mentioned	 previously,	 zebrafish	 has	 the	 advantage	 of	 being	 easily	
genetically	modified.	Indeed,	GAL4-UAS	transgenic	lines	have	been	generated	to	enable	the	










ortholog	 in	 zebrafish	 which	 makes	 it	 relevant	 for	 the	 study	 of	 human	 diseases	 [27].	
Interestingly,	many	CNS-related	disorders	have	been	successfully	modeled	in	the	past	such	as	
Amyotrophic	Lateral	Sclerosis	and	Spinal	Muscular	Atrophy,	epilepsy,	and	autism	[28-32].	The	












model	 of	 GE	 using	 the	 CRISPR/CAS9	 mutagenesis	 system.	 Using	 this	 technique,	 one	 can	
introduce	insertion/deletion	of	nucleotides	(indels)	in	a	region	of	a	gene	of	interest,	that	can	
potentially	lead	to	deleterious	mutations	and	knock-out	the	gene	of	interest.	This	is	done	by	
injecting,	 in	 the	 first	 cell	 of	 the	 fertilized	 embryo,	 CAS9	 mRNA	 and	 a	 guide	 RNA	 (gRNA),	










In	 such	 light,	 generating	a	 zebrafish	 knock-out	mutant	of	gldc	 is	 the	 first	 step	 to	modeling	
severe	 GE	 since	 it	 will	 help	 understand	 the	 function	 of	 this	 protein	 and	 the	 effect	 of	 its	














Generating	 a	 loss-of-function	 mutant	 to	 model	 GE	 in	 zebrafish	 brings	 to	 light	 a	 few	




versus	 neurotransmission	 to	 the	 disease	 symptoms,	 and	 whether	 they	 are	 linked	 or	
independent	pathogenic	mechanisms,	is	still	unclear.	As	described	above,	glycine	acts	as	an	
inhibitory	 neurotransmitter	 in	 the	 CNS	when	 it	 binds	 to	 glycinergic	 synapses,	 and	 as	 a	 co-
agonist	 of	 the	 NMDA	 receptors	 at	 the	 excitatory	 glutamatergic	 synapse.	 Thus,	
hyperglycinemia	 in	 the	 brain,	 as	 occurs	 in	 GE,	 should	 lead	 to	 defective	 signaling	 at	 these	
 14 
synapses.	 This	 aspect	 of	 pathogenicity	 linked	 to	 hyperglycinemia	 in	 GE	 has	 already	 been	
established,	since	the	patients	are	treated	with	a	drug	antagonizing	the	NMDA-glutamatergic	
receptors,	 dextromethorphan,	 to	 alleviate	 the	 seizures,	 and	 the	 glycinergic	 receptors	
antagonist	 strychnine	has	been	 tried	 in	 the	past	 [36].	However,	 the	metabolic	 facet	of	 the	
















The	 mass	 spectrometry	 analysis	 of	 the	 mutant	 gldc	 fish	 was	 performed	 by	 different	
contributors:	 the	 metabolomics	 platform	 of	 the	 Research	 Center	 of	 the	 University	 of	
Montreal	Hospital	(CR-CHUM)	contributed	to	initial	glycine	dosage	and	the	neurotransmitter	
analysis,	 Izabella	 Pena	of	 the	Children’s	Hospital	 of	 Eastern	Ontario	Research	 Institute	 and	
Department	of	Pediatrics	contributed	to	the	amino	acid	dosage,	and	Kit-Yi	Leung	in	Nicholas	
















light	 cycle	 and	 staged	 as	 described	 previously	 [37].	 They	were	 bred	 according	 to	 standard	






A	 Specific	 gldc	 probe	 corresponding	 to	 the	 5’	 part	 of	 the	 coding	 sequence	 and	 first	 exon	
(951bp	 amplified	 with	 the	 following	 primers:	 Forward-gaaggacctttgtgagattacgg;	 Reverse-	
taatgcaggccagtgagtgag)	 was	 cloned	 within	 the	 pCS2+	 vector	 using	 TOPO	 TA	 cloning	 kit	
(Invitrogen).	 After	 sequencing,	 antisense	 probe	 was	 transcribed	 in	 vitro	 using	 SP6	 RNA	
polymerase.	 Whole-mount	 in	 situ	 hybridization	 of	 zebrafish	 embryos	 was	 performed	 as	








the	 online	 tool	 CRISPRscan	 ((PAM	 site	 is	 indicated	 in	 brackets):	 gggacacctcgggctggta(cgg).	
Synthesis	of	 gRNA	and	Cas9	mRNA	was	performed	as	described	by	 [42].	 Tubingen	 long	 fin	
(TL)	wild-type	embryos	were	collected	for	microinjection.	A	1nL	drop	of	a	mix	of	100	ng/μL	of	









back	 in	 fresh	 water	 in	 isolated	 tanks.	 Genomic	 DNA	 extraction	 was	 performed	 in	 10μL	
(embryos)	 or	 20	μL	 (adult)	 of	 50	mM	NaOH.	 The	 samples	were	boiled	 for	 10	minutes	 and	









of	 genomic	 DNA	 and	 water	 up	 to	 10	 μL.	 The	 PCR	 was	 performed	 in	 a	 LightCycler	 480	
Instrument	 II	 (Roche)	using	white	96	well	plates.	Two-step	Evagreen	PCR	 reaction	protocol	
was	95°C	for	2	min,	then	45	cycles	of	95°C	for	10	sec	and	60°C	for	30	sec,	followed	by	95°C	
for	30	sec,	60°C	 for	60	sec,	 the	 temperature	was	 increased	by	0.02°C/sec	until	95°C	 for	10	




Primers	 were	 designed	 using	 the	 Universal	 Probe	 Library	 Assay	 Design	 Center	 (Roche)	 to	
amplify	 a	 667bp	 fragment	 surrounding	 the	 CRISPR	 target	 site.	 Forward:	
AATGTATTATTTTTGTGTGAACTGTCCC;	 Reverse:	 TTCCGTACTTGGCTCTAGTTTGC.	 The	 PCR	
reactions	were	made	with	0.5	μL	of	dNTP	(10	μM),	0.5	μL	of	each	primers	(10	μM),	2.5	μL	of	
10x	 PCR	 buffer,	 0.125	 μL	 of	 Taq	 DNA	 polymerase	 (GenedireX),	 1	 μL	 of	 genomic	 DNA	 and	
water	up	to	25	μL.	The	PCR	reaction	protocol	was	94°C	for	5	min,	then	35	cycles	of	94°C	for	












20	 hpf	 embryos	 were	 embedded	 in	 low	 melting	 agarose	 and	 covered	 with	 water,	 their	
movements	 inside	 the	 chorion	 were	 recorded	 using	 a	 camera	 for	 20	 minutes.	 The	
Danioscope	software	(Noldus)	was	then	used	to	quantify	the	number	of	bursts	over	time.	At	
7	 dpf,	 larvae	 were	 transferred	 individually	 into	 a	 96-well	 plate	 and	 swim	 distance	 was	





One	gldc	 -/-	mutant	and	one	sibling	7	dpf	 larva	were	placed	 in	 the	center	of	a	water-filled	
petri	dish	and	we	applied	a	water	current	circularly	using	a	wash	bottle.	We	took	videos	and	
tracked	 the	 trajectory	 of	 each	 fish	 and	 recorded	 the	 time	 taken	 to	 immobilize	 after	
application	of	the	water	current.	For	the	swimming	balance	test,	we	placed	7	dpf	gldc	-/-	and	
sibling	larvae	in	two	different	plastic	bottles	filled	with	water,	and	recorded	a	video	over	10	
minutes.	We	generated	a	heat	map	 tracking	 the	movement	of	 the	 larvae	using	 the	Noldus	




















in	 acidified	water	 followed	 by	 acetonitrile	 protein	 precipitation	 and	 sample	 concentration;	







20,000g,	10min,	4°C,	35µL	of	 the	 supernatants	were	 transferred	 to	new	1.5mL	 tubes,	 then	
140µL	(4	volumes)	of	ice-cold	acetonitrile	were	added.	Tubes	were	vortexed	10	sec,	kept	on	
ice	 for	 10min	 and	 centrifuged	20,000g,	 15min,	 4°C.	 Supernatants	were	 transferred	 to	 new	
1.5mL	 tubes,	dried	down	under	a	 stream	of	nitrogen	at	 room	temperature	and	stored	at	 -
80°C.	Just	before	the	analysis,	samples	were	reconstituted	in	35µL	(2-3	embryos)	or	50µL	(4	
embryos)	 of	 ice-cold	 5%	 acetonitrile,	 0.2%	 formic	 acid	 in	 MilliQ	 water,	 vortexed	 and	
centrifuged	10,000g,	5min,	4°C.	Supernatants	were	transferred	to	HPLC	vials	and	kept	at	4°C	
before	injections	of	5µL	in	triplicate	into	a	Nexera	X2	HPLC	system	(Shimadzu).	Separation	of	


















the	 lysate,	 vortexed	 and	 centrifuged	 at	 20.000	 x	 g	 for	 20	 min	 at	 4°C	 allowing	 phase	
separation.	 The	 supernatant	 containing	 polar	 metabolites	 was	 collected	 and	 dried	 under	
nitrogen.	The	metabolite	extract	was	resuspended	in	HPLC	grade	H2O	(Sigma)	and	used	for	
liquid	 chromatography-tandem	mass	 spectrometry	 analysis	 (LC-MSMS).	 An	 ACQUITY	 UPLC	
BEH	 C18	 1.7µM	 2.1	 x	 100	 mm	 column	 (Waters)	 was	 used	 at	 30o	 C	 for	 reverse-phase	
chromatography.	 0.5	 mM	 Tridecafluoroheptanoic	 acid	 (TDFHA)	 in	 water	 was	 used	 as	 the	
aqueous	mobile	phase	and	0.5	mM	TDFHA	in	acetonitrile	as	the	organic	phase	at	a	flow	rate	
of	 650	 μL/min.	 Detection	 of	 amino	 acids	 analytes	 was	 performed	 in	 a	 Waters	 TQS	 triple	
quadrupole	 mass	 spectrometer	 operating	 in	 the	 positive	 ion	 mode	 and	 using	 a	 multiple	
reaction	monitoring	(MRM)	method	adapted	from	a	published	procedure	[47].	Processing	of	
the	 chromatograms	 obtained	 by	 LC-MSMS	 was	 done	 using	 TargetLynx	 (Waters),	 including	
peak	detection,	peak	 integration	and	concentration	estimation	based	on	calibration	curves.	













5,7	 nM	 final	 concentration	 of	 Illumina	 Truseq	 index	 and	 15	 PCR	 cycles	 was	 required	 to	




(2x80bp)	 using	 2.2	 pM	 of	 the	 pooled	 library.	 Around	 100-200	M	 paired-end	 PF	 reads	was	




95%	 of	 high	 quality	 reads	 were	 mapped	 onto	 the	 zv9	 version	 of	 the	 zebrafish	 genome	
(ensemble	release	77)	using	TopHat	version	2.0.10.		
Differential	 gene	 expression	 analysis	 was	 assessed	 by	 DeSeq2	 package	 using	 R	 software.	
Differential	 gene	 expression	was	 filtered	 on	 a	 False	 Discovery	 Rate	 (or	 adjusted	 p	 value	 >	
0.05).	Pathway	analysis	was	performed	using	DAVID	bioinformatics	resources	[48].	The	list	of	
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differentially	 expressed	 genes	 was	 uploaded	 onto	 DAVID	 analysis	 wizard	 and	 a	 list	 of	 all	





gldc:	 Forward:	 tctcctttcagcccaacagt,	 Reverse:	 tctggagttcagataggctttga.	 All	 other	 primer	
sequences	are	available	upon	request.	Reverse	transcription	was	performed	from	500ng	of	
total	RNA	using	the	superscript	VILO	reverse	transcription	mix	(Invitrogen).	Quantitative	PCR	
was	 performed	 on	 2	 µL	 of	 1:10-diluted	 cDNA	 using	 SYBR	 Green	 I	 master	 (Roche)	 on	 a	




Gldc	 -/-	 and	 +/+	 embryos	 were	 anaesthetized	 in	 0.2%	 tricaine,	 fixed	 with	 4%	
paraformaldehyde	for	1h30	at	room	temperature	(or	in	Dent’s	overnight	at	4ºC	for	pH3	IHC).	
Samples	were	stored	in	Methanol	at	-80°C	until	use.	Immunohistochemistry	was	performed	
as	previously	described	 [49].	 Briefly,	 fixed	 fish	were	blocked	and	permeabilized	with	 -80ºC	
acetone	for	7-15	minutes,	0.1%	Triton	X100	diluted	 in	PBS	washes,	 incubated	for	1-2h	with	
block	 solution	 (PBS	 0.1%Triton,	 2%	 NGS,	 2%BSA,	 1%DMSO)	 at	 RT	 and	 then	 incubated	








Gldc	 -/-	and	+/+	 larvae	 (3	and	7	dpf)	were	anesthetized	 in	0.2%	tricaine,	and	embedded	 in	
low	 melting	 agarose	 in	 the	 dorsal-up	 position.	 They	 were	 kept	 hydrated	 during	 the	
fluorescence	 imaging	 under	 the	 confocal	 microscope	 (Olympus	 BX61W1	 equipped	 with	 a	
Quorum	Technology	spinning	disk	head	connected	to	a	Hamamatsu	ORCA-ER	camera).	Using	















Total	 RNAs	 from	 24	 hpf	 embryos	 was	 extracted	 using	 phenol-chloroform	 RNA	 extraction	
method	and	500ng	of	total	RNAs	were	retro-transcribed	using	VILO	RT	enzyme	(Invitrogen).	
1µl	of	 retro-transcription	 reaction	was	used	 to	amplify	 the	 full-length	 cDNA	of	GlyT1	using	
the	 following	 primers:	 Forward:	 ATGAACAGCAGAAAGAATGGAGCA;	 Reverse:	
CTATGCGCTGGGTGTGGG.	The	PCR	product	was	cloned	within	the	pCS2+	vector	using	TOPO	





than	 two	 groups,	 one-way	 and	 two-way	ANOVA	were	 used	 as	 required.	 The	 post-hoc	 test	






























acid	 (fig.	 IV.1.B-C).	 Using	 the	 high-resolution	melting	 (HRM)	 analysis	 [42],	 we	 could	 easily	
identify	all	 three	genotypes	(+/+,	 -/+,	 	 -/-)	 (fig.	 IV.1.B).	We	confirmed	gldc	knock-out	by	RT-
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qPCR	and	showed	that	-/-	embryos	have	reduced	levels	of	gldc	expression	compared	to	their	
siblings,	 as	 seen	 in	 patients	 [51].	 	 More	 importantly,	 Liquid	 Chromatography	 –	 Mass	
Spectrometry	(LC-MS)	analysis	of	glycine	levels	 in	whole	7	dpf	 larvae	supported	the	loss-of-
function	 nature	 of	 the	 mutation,	 since	 gldc	 -/-	 larvae	 display	 4	 times	 more	 accumulated	
glycine	 than	 their	 siblings	 (fig.	 IV.1.D).	 The	 fact	 that	 only	 homozygous	 larvae	 depicted	
hyperglycinemia	 is	also	consistent	with	the	recessive	nature	of	the	disease,	confirming	that	
one	allele	of	gldc	 is	enough	to	maintain	glycine	metabolism	homeostasis.	Altogether,	these	















	 We	 monitored	 the	 survival	 of	 the	 three	 genotypes	 expected	 upon	 crosses	 of	
heterozygotes	fish:	gldc	+/+	(wild	type),	gldc	-/+,	and	gldc	-/-.	While	most	of	the	gldc	+/+	and	
-/+	larvae	survived	for	the	first	10	days	post	fertilization,	all	the	gldc	-/-	larvae	died	between	7	
and	9	dpf	 (fig.	 IV.2.A).	 Although	 there	was	no	 evident	 explanation	 for	 this	 lethality,	 it	was	
interestingly	 reminiscent	 of	 the	 early	 death	 of	 neonates	 in	 the	 severe	 form	 of	 GE.	 After	
measuring	 the	body	 length,	eye	size	and	 inter-eye	distance	of	 -/-	 larvae	compared	 to	 their	
siblings,	we	did	not	notice	any	morphological	abnormalities	of	the	mutant	larvae	(fig.	IV.2.B).		
However,	gldc	-/-	 larvae	from	6	dpf	depict	an	evident	hyperpigmentation,	which	is	practical	
to	 easily	 separate	 them	 from	 the	 siblings	 (fig.	 IV.2.C).	 This	 hyperpigmentation	 phenotype	




output	 in	 zebrafish	 embryos	 occurring	 between	 17-21	 hpf	 and	 consisting	 of	 frequent	 un-
evoked	movements	of	the	tail	in	the	chorion	[25].	Analysis	of	this	motor	behavior	indicated	a	
decrease	 in	 coiling	 frequency	 of	gldc	 -/-	 embryos	 compared	 to	 their	 siblings	 (1.46	±	 0.31,	
12.81	 ±	 2.73;	 fig.	 IV.2.D).	 At	 the	 larval	 stage,	 we	 assayed	 the	 swimming	 activity	 of	 gldc	





compare	with	 the	 human	 patient	 condition.	 Since	 hypotonia	 and	 lethargy	 are	 respectively	
defined	 as	 a	 state	 of	 low	muscle	 tone	 and	 a	 lack	 of	 vigor,	 we	 tested	 the	 capacity	 of	gldc	
larvae	to	swim	against	a	water	current.	When	we	tracked	the	path	swam	by	the	larvae	after	
applying	a	circular	water	current,	as	well	as	the	time	needed	to	immobilize	in	the	dish	(e.g.	
stabilize	 their	 position),	 we	 noticed	 abnormalities	 in	 gldc	 -/-	 behavior.	 Indeed,	 while	 the	
siblings	can	actively	swim	against	the	water	current	in	order	to	maintain	their	position,	gldc	-
/-	mutants	were	 unable	 to	 fight	 against	 it	 and	 to	 stabilize	 their	 position.	 As	 a	 result,	 they	
were	 passively	 carried	 through	 the	 dish	 by	 the	water	 current	 in	 a	 lethargic	 and	 hypotonic	
fashion	 (see	 swimming	 tracks	 in	 fig.	 IV.2.F).	Moreover,	 because	 of	 their	 passive	 hypotonic	





their	 environment,	 indicating	 a	 swimming	 balance	 impairment	 (fig.	 3H-I).	 Taken	 together	



























































































































































































































Riché et al., Figure 3
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of	the	water	current	compared	to	gldc	+/+	(both	n=15)	(t-test,	p=0.0008).	H.	Heatmap	tracking	of	the	swimming	





3. Metabolomics	 analysis	 indicates	 broad	 metabolic	 perturbations	 in	 gldc	 -/-	
larvae.	
	 After	characterizing	the	disease-related	phenotype	of	gldc	-/-	mutants,	we	sought	to	
describe	 the	 molecular	 mechanisms	 involved	 in	 pathogenicity.	 Since	 glycine	 acts	 as	 an	
essential	amino-acid	as	well	as	a	neurotransmitter	in	the	CNS,	we	conducted	a	broad	assay	of	
metabolites	 by	 LC-MS	 in	 order	 to	 titrate	 the	 level	 of	 all	 proteinogenic	 and	 the	main	 non-
proteinogenic	 amino	 acids,	 as	well	 as	 the	main	 neurotransmitters,	 in	 7	 dpf	gldc	 -/-	 larvae	
compared	to	their	siblings.	Interestingly,	we	found	that	extracts	from	gldc	-/-	larvae	showed	
a	 significant	 increase	 in	 many	 amino	 acids	 other	 than	 glycine,	 such	 as	 sarcosine,	 proline,	
valine,	cystathionine,	leucine,	and	arginine	(fig.	IV.3.A).	This	suggests	that	the	degradation	of	
amino	acids	other	than	glycine	is	also	impaired	when	gldc	is	knocked-out,	which	might	play	a	
role	 in	 GE	 pathogenesis.	 Moreover,	 we	 found	 that	 gldc	 -/-	 larvae	 depicted	 a	 significant	
reduction	 in	 the	 levels	 of	GABA	 and	 glutamate	 compared	 to	gldc	+/+	 (fig.	 IV.3.B)	whereas	
dopamine	 and	 serotonin	 levels	were	 not	 significantly	 affected.	 Likewise,	 this	 suggests	 that	
gldc-KO	impairs	the	metabolism	of	amino-acid/neurotransmitters	other	than	glycine.		
The	GCS	is	also	involved	in	folate	one	carbon	metabolism	(FOCM)	since	by	degrading	
glycine,	gldc	 donates	 one	 carbon	 units	 to	 this	metabolic	 cycle	 [8].	 The	 output	 of	 FOCM	 is	
mainly	building	blocks	for	the	cell	important	for	growth	and	proliferation	[23].	Interestingly,	
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Greene	et	 al.	 showed	 that	 FOCM	homeostasis	 is	 specifically	 affected	 in	 a	mouse	model	 of	
GLDC-KO	and	that	 this	 imbalance	may	be	 involved	 in	neural	 tube	closure	defects	 [8].	Thus,	
we	 examined	 the	 levels	 of	 FOCM-related	 metabolites	 in	 gldc	 -/-	 larvae	 in	 order	 to	 check	







increased	 in	gldc	 -/-	 compared	 to	+/+	 at	 an	 earlier	 time	 point	 to	 see	 if	 the	 defects	 in	 the	
amount	 of	 these	 compounds	 were	 already	 present	 in	 gldc	 -/-.	 Interestingly,	 whereas	 the	
levels	 of	 glycine	 are	 already	 increased	 at	 2	 dpf	 in	gldc	 -/-,	 there	was	 no	 difference	 in	 the	
levels	of	 lactate,	GABA,	glutamate,	and	all	 the	amino	acids	except	sarcosine	 in	gldc	 -/-	and	
+/+	at	2	dpf	(fig.	IV.3.E).	This	suggests	that	there	is	a	progressive	accumulation	of	lactate	and	
amino	 acids,	 and	 a	 progressive	 decrease	 in	 GABA	 and	 glutamate	 over	 time	 that	 might	
contribute	to	the	death	of	mutant	larvae	at	7-9	dpf.	
Altogether,	 these	 results	 demonstrate	 that	 gldc	 loss-of-function	 induces	 previously	
unknown	broad	metabolic	perturbations.	Indeed,	it	not	only	affects	glycine,	but	also	the	level	
of	other	amino	acids	and	neurotransmitters	(including	GABA	and	Glutamate),	and	it	leads	to	
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Riché et al., Figure 4
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Figure	 IV.3:	 Metabolomics	 analysis	 indicates	 broad	 metabolic	 perturbations	 in	 gldc	 -/-	 larvae.	 A.	 LC-MS	
analysis	of	 the	 levels	of	 the	main	proteogenic	and	non-proteogenic	amino	acids	at	7	dpf	 reveals	a	 significant	
increase	 in	 sarcosine,	proline,	 glycine,	 valine,	 cysthationine,	 leucine,	and	arginine	 in	gldc	 -/-	 compared	 to	+/+	
(n=4)	 (t-test,	 respectively,	p=0.035,	p=0.0062,	p<0.00001,	p=0.0006,	p=0.0006,	p=0.029,	and	p=0.0006).	B.	LC-
MS	analysis	of	the	main	neurotransmitter	at	7	dpf	reveals	a	significant	decrease	in	glutamate	and	GABA	in	gldc	-








4. Transcriptomics	 analysis	 reveals	 differences	 in	 the	 expression	 of	 cell	 cycle,	
proliferation,	and	metabolism-related	genes	in	the	gldc	-/-	mutants	
	 In	 the	continuity	of	 the	unbiased	metabolomics	analysis	 in	 the	gldc	 -/-	mutants,	we	
carried	out	a	whole	transcriptome	analysis	by	deep-sequencing	of	RNAs	extracted	from	7	dpf	
gldc	-/-	and	+/+	larvae.	There	were	408	differentially	expressed	genes	in	gldc	-/-	versus	gldc	
+/+	 larvae,	 of	 which	 153	 were	 up-	 and	 255	 were	 downregulated	 (fig.	 IV.4.A).	 Using	 gene	
clustering	and	pathway	analysis	from	the	list	of	significant	differentially	expressed	genes,	we	




Hartnup	 disease	 (fig.	 IV.4.B)	 [55].	 Unexpectedly,	 only	 few	 brain-specific	 genes	were	 found	











Altogether,	 these	 transcriptomic	 data	 suggest	 that	 the	 majority	 of	 genes	 whose	
expression	is	affected	by	GLDC-KO	are	related	to	metabolism	and	that,	surprisingly,	no	major	
transcriptomic	 changes	occur	 in	 the	CNS.	Moreover,	 these	data	pointed	out	 that	 cell-cycle	





Figure	 IV.4:	 Transcriptomics	 analysis	 reveals	 differences	 in	 the	 expression	 of	 cell	 cycle,	 proliferation,	 and	
metabolism-related	genes	in	the	gldc	-/-	mutants.	A.	RNA	sequencing	analysis	of	7	dpf	larvae	reveals	that	408	
genes	are	differentially	expressed,	with	255	up-regulated	and	153	downregulated,	in	gldc	-/-	compared	to	+/+.	








5. The	 main	 brain	 networks	 are	 not	 affected	 by	 gldc-KO	 despite	 a	 transient	
decrease	of	proliferation	in	gldc	-/-	brain		
The	 imbalance	 in	 the	 expression	 of	 proliferation-related	 genes	 observed	 in	gldc	 -/-	
mutants	from	the	RNAseq	analysis	led	us	to	investigate	the	proliferation	homeostasis	in	the	
brain	 throughout	 neurodevelopment.	 Moreover,	 a	 decreased	 proliferation	 at	 embryonic	








may	 have	 an	 impact	 on	 the	 content	 of	 specific	 neural	 cell	 populations,	 we	 sought	 to	
investigate	 whether	 the	 major	 cell	 populations	 and/or	 structures	 of	 the	 brain	 neuronal	
networks	were	affected.	First,	we	checked	the	general	morphology	of	neuronal	fibers	in	the	
brain	of	gldc	-/-	larvae	compared	to	their	siblings	by	immunolabelling	acetylated	tubulin	(ac-
Tub).	 No	 difference	 in	 the	 labeling	 of	 axonal	 tracks	 in	 the	 brain	 of	 gldc	 -/-	 and	 +/+	was	
observable	at	24	hpf,	 nor	 later	 stages	 (4	dpf)	 (fig.	 IV.5.B).	 Then,	we	aimed	at	 checking	 the	
structure	and	neural	 content	of	 (i)	 the	GABAergic	network	using	 the	dlx5-6:GFP	 transgenic	
line	 (fig.	 IV.5.C)	 [39],	 (ii)	 glutamatergic	 network	 using	 the	 vglut2:RFP	 transgenic	 line	 (fig.	
IV.5.D)	 [56],	 (IV)	 the	 dopamine	 network	 through	 immunolabelling	 against	 tyrosine	
 40 
hydroxylase	 (TH)	 (fig.	 6E),	 as	 well	 as	 (iv)	 the	 cerebellum	 through	 immunolabelling	 against	
paravalbumin	7	 (PAV7,	 labeling	Purkinje	cells)	and	vglut1	 (labeling	granule	cells)	 (fig.	 IV.5.F	




is	 a	 sensitive	 measure	 of	 neural	 tube	 defects	 and	 found	 no	 aberrant	 development	 or	
migration	 of	 the	 trigeminal,	 facial	 and	 vagal	 motorneurons	 at	 3	 dpf	 gldc	 -/-	mutants	 (fig.	
IV.5.H)	[56].	These	results	indicate	that	the	transient	proliferation	deficit	observed	at	3	dpf	in	
gldc	-/-	does	not	lead	to	any	major	morphological	defect	in	other	brain	networks.	Thus,	it	is	
likely	 to	 solely	 reflect	 a	 transient	difference	 in	 the	proliferating	 rate	of	 neural	 progenitors.	
Although	 we	 did	 not	 check	 the	 integrity	 of	 the	 glial	 population	 which	 might	 have	 been	
affected	 by	 this	 transient	 difference	 in	 the	 proliferation	 rate	 of	 neural	 progenitors,	 it	 has,	
whatsoever,	no	 consequence	on	 the	brain	neural	 content	analyzed	here,	 and	 therefore	no	
specific	 relevance	 to	 the	 motor	 phenotype.	 Moreover,	 the	 fact	 that	 the	 branchiomotor	












D.	 Using	 the	 vGluT2:RFP	 transgenic	 line	 to	 label	 the	 glutamatergic	 network	 did	 not	 reveal	 any	 gross	
morphological	difference	between	gldc	 -/-	 and	+/+	 7	dpf	 larvae	 (both	n=6).	 E.	 Immunohistochemistry	against	
tyrosine	hydroxylase	labelling	dopaminergic	neurons	did	not	reveal	any	gross	morphological	difference	between	
gldc	-/-	and	+/+	at	5	dpf	(both	n=6).	F.	Immunohistochemistry	against	paravalbumin	7	labels	purkinje	cells	of	the	
cerebellum	 on	 5	 dpf	 gldc	 -/-	 (n=5)	 and	 +/+	 (n=6)	 larvae.	 G.	 Immunohistochemistry	 against	 vGluT1	 labelling	
granule	cells	of	the	cerebellum	did	not	reveal	any	gross	morphological	difference	between	5dpf	gldc	-/-	and	+/+	
larvae	 (both	n=6).	H.	Using	 the	 islet1:GFP	 transgenic	 line	 to	 label	 the	branchiomotor	neuron	network	did	not	
reveal	any	gross	morphological	difference	between	gldc	-/-	and	+/+	3	dpf	larvae	(both	n=4).	I.	Quantification	of	
the	number	of	Ph3	positive	cells	revealed	a	significant	decrease	of	proliferating	cells	in	gldc	-/-	compared	to	+/+	
at	 1	 (both	 n»35)	 and	 3	 dpf,	 but	 not	 7	 dpf	 (respectively,	 n=23	 and	 n=37)	 (t-test,	 respectively,	 p=0.0223	 and	
p=0.014).	J.	Quantification	of	the	number	of	dlx5/6:GFP	positive	cells	did	not	reveal	any	difference	between	gldc	
-/-	 and	 +/+	 (both	 n=5).	 K.	 Quantification	 of	 the	 number	 paravalbumin	 7	 positive	 cells	 did	 not	 reveal	 any	
difference	between	gldc	-/-	(n=5)	and	+/+	(n=6).	
	




above.	 As	 a	 neurotransmitter,	 glycine	 is	 involved	 in	 synaptic	 signaling	 through	 binding	 to	
glycine	receptors	at	inhibitory	synapses	and	to	NMDA	receptors	at	excitatory	synapses.	Thus,	
we	wondered	whether	 the	 hyperglycinemia	 observed	 in	gldc	 -/-	 larvae	was	 affecting	 both	
inhibitory	and	excitatory	synaptic	transmission.	To	test	this,	we	performed	a	pharmacological	
assay	 treating	 gldc	 embryos	 with	 either	 a	 glycine	 receptor	 antagonist	 (strychnine)	 or	 an	
NMDA	 receptor	 antagonist	 (dextromethorphan).	 Overnight	 treatment	 with	 a	 low	 dose	 of	
strychnine,	 a	 dose	 not	 affecting	 WT	 larval	 behavior,	 rescued	 significantly	 the	 hypotonic	
swimming	 phenotype	 of	 7	 dpf	 gldc	 -/-	 larvae	 (fig.	 IV.6.A).	 Moreover,	 treatment	 with	
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dextromethorphan	 slightly	 decreased	 the	 hypotonic	 coiling	 behavior	 of	 gldc	 -/-	 embryos,	
although	it	was	not	significant	since	the	treatment	had	a	strong	activity-enhancing	effect	on	
the	 siblings	 as	 well	 (fig.	 IV.6.B).	 However,	 daily	 dextromethorphan	 treatment	 significantly	
rescued	 the	 hypotonic	 swimming	 phenotype	 of	gldc	 -/-	7	 dpf	 larvae	 compared	 to	 vehicle-
treated	gldc	 -/-	 larvae	 (fig.	 IV.6.C).	 	 These	 results	 show	 that	 the	hyperglycinemia	 is	 indeed	
over-activating	 both	 glycine	 receptors	 and	 NMDA	 receptors	 throughout	 the	 brain,	 which	
contribute	to	the	GE-related	hypotonic	motor	phenotype.		
Remarkably,	the	hyperglycinemia	at	the	synapse	is	expected	to	be	exacerbated	in	gldc	
-/-	 mutants.	 Indeed,	 as	 presented	 earlier,	 our	 transcriptomic	 assay	 showed	 that	 the	
expression	of	glycine	transporter	1	(GlyT1)	is	significantly	reduced	in	gldc	-/-	mutants.	GlyT1	
is	 localized	 at	 the	 membrane	 of	 glial	 cells	 surrounding	 glycinergic	 and	 NMDA-excitatory	




et	 al.,	 2004).	 Altogether,	 this	 indicates	 that	 the	 hyperglycinemia	 at	 the	 synapse	 caused	 by	
gldc	 loss-of-function	 is	 likely	 to	 be	 worsened	 by	 these	 transcriptomic	 and	 metabolic	
perturbations.	 Therefore,	 we	 hypothesized	 that	 diminishing	 the	 hyperglycinemia	 at	 the	
synapse	by	overexpressing	GlyT1	 in	gldc	 -/-	embryos	may	 improve	 their	motor	deficits.	 To	
test	this	assumption,	we	cloned	the	GlyT1	cDNA	and	in	vitro	synthesized	its	mRNA	in	order	to	






Altogether,	 these	 results	 confirm	 that	 the	 hyperglycinemia	 of	 gldc	 -/-	 larvae	 is	
affecting	 normal	 glycinergic	 and	 NMDA	 signaling.	 Moreover,	 they	 show	 that	 there	 is	 an	











treated	 -/-	 vs.	 sib/+,	 p=0.0002).	 B.	Overnight	 treatment	with	 dextromethorphan	 50uM	 slightly	 decreases	 the	
hypotonic	coiling	of	gldc	-/-	(n=23)	compared	to	vehicle	treated	gldc	-/-	embryos	(n=27)	at	21	hpf,	although	not	
significantly	since	the	treatment	also	has	a	strong	activity-enhancing	effect	on	the	siblings	(vehicle-treated	sib/+	
vs.	 dextromethorphan-treated	 sib/+,	 p<0.0001;	 vehicle-treated	 sib/+	 vs.	 -/-,	 p=0.0013;	 dextromethorphan-
treated	sib/+	vs.	-/-,	p=0.0024).	C.	Daily	dextromethorphan	25uM	treatment	over	7	dpf	significantly	rescues	the	
hypotonic	 swimming	 of	 gldc	 -/-	 (n=4)	 at	 7	 dpf,	 compared	 to	 vehicle-treated	 gldc	 -/-	 larvae	 (n=6)	 (p=0.0129;	
vehicle-treated	sib/+	vs.	-/-,	p=0.0017).	D.	First-cell	stage	GlyT1	mRNA	injection	rescues	the	coiling	defect	of	gldc	
-/-	 embryos	 at	 21	 hpf	 compared	 to	 GFP	 injected	 gldc	 -/-	 (n»15,	 N=4)	 (p=0.0064;	 GFP-injected	 sib/+	 vs.	 -/-,	
p=0.015).	E.	Model	representation	of	NMDA	and	glycine	synapses	of	gldc	-/-	compared	to	+/+.	Gldc	-/-	have	an	



















In	 this	 work,	 we	 generated	 the	 first	 zebrafish	 model	 of	 GLDC-mediated	 GE	 by	
knocking-out	 gldc	 using	 CRISPR/CAS9,	 with	 the	 goal	 of	 characterizing	 the	 molecular	
mechanisms	underlying	GE.	GLDC	being	the	most	commonly	mutated	gene	in	GE,	we	hoped	
to	 recapitulate	 the	 most	 common	 form	 of	 the	 disease	 by	 generating	 a	 loss-of-function	
mutant.	Moreover,	by	disrupting	the	coding	reading	frame	of	both	alleles,	we	modeled	the	




for	 unbiased	 changes	 in	 the	 metabolome	 and	 transcriptome,	 and	 our	 analysis	 revealed	
unexpected	imbalances	in	the	metabolism	of	amino	acids	and	neurotransmitters	other	than	
glycine.	Moreover,	we	found	that	although	gldc	-/-	mutants	do	not	show	defect	in	the	FOCM	
and	 that	 they	display	 lactic	acidosis,	accumulation	of	amino	acids,	and	a	decrease	 in	GABA	
and	 glutamate	 at	 stages	 preceding	 their	 death.	 We	 also	 found	 that	 the	 homeostasis	 of	
cellular	 proliferation	 is	 disrupted	 at	 the	 transcriptomic	 level.	 Consistently,	we	 showed	 that	
cell	 proliferation	 in	 the	 brain	 is	 slowed	 down	 during	 development,	 leading	 to	 a	 transient	
decrease	 in	 the	 number	 of	 dividing	 cells	 at	 1	 and	 3	 dpf.	 However,	 this	 decrease	 in	
proliferation	 is	 not	 associated	 with	 any	 gross	 morphological	 anomaly	 in	 the	 main	 brain	
structures	 or	 neuronal	 networks	 of	 gldc	 -/-,	 suggesting	 that	 this	 transient	 reduction	 of	
proliferation	 may	 be	 the	 consequence	 of	 metabolic	 perturbation,	 without	 having	 direct	
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consequences	on	the	motor	phenotype.	The	 intact	morphology	of	the	brain	of	gldc	-/-	also	
supports	 the	 fact	 that	 the	 decrease	 in	 the	 levels	 of	 glutamate	 and	 GABA	 is	 caused	 by	 a	









KO	 could	 worsen	 the	 level	 of	 glycine	 in	 the	 synaptic	 cleft.	 In	 fact,	 GlyT1	 expression	 is	
significantly	decreased	in	gldc	-/-	compared	to	their	siblings,	suggesting	that	the	clearance	of	
glycine	 from	 the	 cleft	 may	 be	 slowed.	 Moreover,	 our	 metabolomics	 analysis	 revealed	 a	
significant	increase	of	sarcosine	in	gldc	-/-	larvae,	a	non-proteogenic	amino	acid	known	to	be	
a	potent	antagonist	of	GlyT1	activity.	 Indeed,	 sarcosine	has	 raised	a	 significant	 therapeutic	




Consistent	 with	 the	 excess	 of	 glycine	 at	 the	 synapse,	 we	 showed	 that	 the	
overexpression	of	GlyT1	 in	the	embryo	was	sufficient	 to	 fully	 rescue	their	motor	condition.	
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dextromethorphan)	 and/or	 (ii)	 reducing	 the	 level	 of	 glycine	 in	 the	 body	 (e.g.	 sodium	
benzoate),	but	the	efficacy	of	these	treatments	is	limited	and	the	quality	of	life	of	surviving	
GE	 patients	 remains	 very	 diminished.	 Here	 we	 propose	 that	 agonizing	 GlyT1	 activity	 may	




therapeutic	 strategy	 would	 require	 the	 design	 and	 development	 of	 GlyT1	 agonists	 with	
varying	potency,	whose	activity	could	be	efficiently	adjusted	to	each	GE	patients.		
	 At	 this	 juncture,	 our	GLDC-KO	 zebrafish	model	 could	be	of	 prime	 interest	 for	 drug-
screen	purposes.	Indeed,	we	showed	that	motor	phenotypes	relevant	to	the	disease	can	be	
accurately	observed	and	quantified	as	early	as	20	hours	post	fertilization.	Moreover,	we	used	
an	 automated	 quantification	 of	 coiling	 behavior	 that	 would	 allow	 for	 high-throughput	




Our	 work	 shed	 new	 light	 on	 another	 facet	 of	 GE	 as	 our	 metabolomics	 analysis	
unraveled	 unexpected	 changes	 in	 other	 metabolites	 than	 glycine	 itself.	 Such	 a	 broad	
metabolic	defect	linked	to	GLDC	loss-of-function	has	never	been	reported	in	other	GE	animal	
models	 nor	 in	 human	 patients.	 Indeed,	 there	 is	 a	 significant	 increase	 in	 the	 amount	 of	
multiple	amino	acids	as	well	as	a	decrease	in	the	level	of	glutamate	and	GABA.	Since	these	
neurotransmitters	 can	be	 synthetized	 from	basic	amino-acids	and	 since	no	major	defect	 in	
glutamatergic	and	GABAergic	networks	were	noticed,	we	assumed	that	these	changes	in	the	
level	 of	 GABA	 and	 glutamate	 are	 most	 likely	 due	 to	 a	 defect	 in	 their	 metabolism.	





leading	 to	 a	 peculiar	maple	 syrup	 smell.	 Remarkably,	MSUD	patients	 show	 some	 common	
symptoms	to	GE	patients,	 such	as	hypotonia,	 seizures	and	 the	only	efficient	 treatment	 is	a	
BCAA-free	 diet.	 In	 order	 to	 test	 the	 effect	 of	 an	 excess	 of	 valine	 or	 leucine	 on	 the	motor	







patients,	 such	 as	 dosage	 of	 BCAAs,	 lactate	 in	 the	 blood	 and/or	 urine,	 and	 glutamate	 and	
GABA	 in	 the	 CSF.	 This	 could	 allow	 identifying	 putative	 defects	 in	 other	 amino	 acid	
metabolism,	 and	 therefore	 opening	 new	 therapeutic	 strategies	 that	 may	 not	 have	 been	
considered,	such	as	a	BCAA-free	diet.	 In	this	regard,	a	potential	molecular	 link	between	GE	
and	MSUD	might	involve	the	dihyrolipoamide	dehydrogenase	(DLD)	subunit,	which	is	part	of	
both	 the	GCS	and	 the	BCKD	complexes.	DLD	 is	also	 involved	 in	other	metabolic	 complexes	
that	are	the	α-ketoglutarate	and	pyruvate	dehydrogenases.	 In	human,	DLD-deficiency	 leads	









(BCAT)	 degrades	 BCAA-related	 α-keto	 acid	 metabolites,	 donating	 nitrogen	 to	 alpha	 α-
ketoglutarate	 and	 yielding	 glutamate.	 The	 α-keto	 acid	 metabolites	 are	 then	 degraded	 by	
BCKD.	In	gldc	-/-	mutants,	there	appears	to	be	a	deficiency	in	BCAA	metabolism,	which	could	





Previous	 studies	 from	 Greene	 et	 al.	 showed	 an	 imbalance	 in	 folate-related	
metabolites	in	Gldc	knock-out	mice.	However,	we	did	not	detect	any	anomaly	in	the	levels	of	
FOCM	 compounds	 in	 gldc	 -/-	 	 larvae	 [8].	 One	 possible	 explanation	 for	 this	 is	 that	 serine	
degradation,	another	source	of	one-carbon	units	to	the	FOCM,	could	compensate	for	the	loss	




thickening	 of	 the	 neural	 plate	 that	 is	 secondarily	 opened	 from	 the	 inside	 [63].	 Such	 a	
difference	 in	 development	 may	 explain	 why	 no	 NTDs	 were	 observed	 in	 gldc	 -/-	 zebrafish	
embryos.	Thus,	these	results	suggest	that	FOCM	disturbances	may	not	be	directly	involved	in	
the	motor	dysfunction	associated	with	GE,	but	rather	specifically	in	neural	tube	defects.		
Altogether,	 the	 present	 work	 confirmed	 the	 central	 role	 played	 by	 the	
hyperglycinemia	in	motor	dysfunction	associated	with	GE,	but	also	unraveled	an	unexpected	
broader	metabolic	disturbance	that	could	also	be	essential	in	GE	pathogenesis.	Both	aspects	









and	 glycine	 cause	 a	 significant	 reduction	 of	 coiling	 behavior	 at	 21	 hpf	 (ANOVA	 p=0.0348,	 then	 post-hoc,	
respectively,	p=0.0060	and	p=0.0223),	but	not	when	treating	with	valine	or	glycine	alone	(n»35,	N=4).	B.	Daily	


















































eventually	 open	 new	 therapeutic	 avenues	 for	 the	 treatment	 of	 patients.	We	 showed	 that	
gldc	 -/-	 fish	 recapitulate	 GE	 molecularly,	 and	 present	 early	 lethality	 and	 a	 hypotonic	
phenotype	 reminiscent	 of	 GE	 symptoms.	 Unexpectedly,	 we	 identified	 a	 broad	 defect	 in	
metabolism	 of	 other	 amino	 acids	 and	 neurotransmitters	 than	 glycine,	 as	 well	 as	 lactic	




NMDA	 and	 glycine	 receptors,	 and	 that	 there	 is	 an	 exacerbated	 hyperglycinemia	 at	 these	
synapses	caused	by	the	downregulation	of	GlyT1	and	the	increase	in	sarcosine.	We	were	able	
to	 rescue	 this	 hypotonic	 behavior	 in	 gldc	 -/-	 fish	 pharmacologically,	 by	 antagonizing	 the	
NMDA	and	glycine	 receptors,	as	well	as	genetically,	by	overexpressing	GlyT1.	These	 results	




as	 well	 as	 in	 human	 patients.	 To	 further	 investigate	 the	 beneficial	 role	 of	 GlyT1	
overexpression	in	our	GE	zebrafish	model,	we	are	currently	generating	UAS:GlyT1	fish,	that,	
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when	 crossed	with	GFAP:GAL4	gldc	mutant	 fish,	will	 overexpress	 GlyT1	 specifically	 in	 glial	
cells.	 In	this	way,	we	hope	to	see	whether	GlyT1	overexpression	in	glial	cells	 in	gldc	-/-	fish	
could	rescue	the	GE-related	phenotype	on	the	long-term.	This	work	would	indicate	whether	
GlyT1	gene-therapy	and	GlyT1	agonists	could	be	good	alternative	treatments	for	GE	patients.	
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